Calendar · pharmadog

Sign In Subscribe

Week of Apr 20, 2026

1

Apr 26, 2026phase 2 completion72d agoCentral Council for Research in Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

Therapy area: Ophthalmology. Indication: Asthenopia (Eye Strain), Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

full page →unani medicine →source: globaldata

Week of Apr 27, 2026

8

Apr 27, 2026phase 2 completion71d agoSMBT Ayurved College and Hospital — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

full page →ayurvedic medicine →source: globaldata

Apr 29, 2026phase 2 completion69d agoMassachusetts Eye and Ear Infirmary — N-acetylcysteine (Phase II Trial Completion)N-acetylcysteine

Therapy area: Ophthalmology. Indication: Cataract, Fuchs Endothelial Corneal Dystrophy (FECD)

full page →N-acetylcysteine →source: globaldata

Apr 30, 2026filing68d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing68d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Choroidal Neovascularization

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing68d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing68d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Diabetic Retinopathy

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing68d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Diabetic Macular Edema

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026phase 2 completion68d agoShenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)umbilical cord mesenchymal stem cells derived apoptotic vesicles

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

full page →umbilical cord mesenchymal stem cells derived apoptotic vesicles →source: globaldata